{"id":"https://openalex.org/W3044516290","doi":"https://doi.org/10.1182/blood.v130.suppl_1.1318.1318","title":"PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of B-Cell Acute Lymphoblastic Leukemia","display_name":"PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of B-Cell Acute Lymphoblastic Leukemia","publication_year":2017,"publication_date":"2017-12-07","ids":{"openalex":"https://openalex.org/W3044516290","doi":"https://doi.org/10.1182/blood.v130.suppl_1.1318.1318","mag":"3044516290"},"language":"en","primary_location":{"id":"mag:3044516290","doi":"https://doi.org/10.1182/blood.v130.suppl_1.1318.1318","is_oa":false,"landing_page_url":"https://ashpublications.org/blood/article/130/Supplement%201/1318/116293/PD-1-Inhibition-Enhances-Blinatumomab-Response-in","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Blood","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016359984","display_name":"Mark Wunderlich","orcid":"https://orcid.org/0000-0002-2166-5146","observed_orcids":["https://orcid.org/0000-0002-2166-5146"]},"institutions":[{"id":"https://openalex.org/I1285204247","display_name":"Cincinnati Children's Hospital Medical Center","ror":"https://ror.org/01hcyya48","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285204247"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Wunderlich","raw_affiliation_strings":["Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"],"raw_orcid":"https://orcid.org/0000-0002-2166-5146","affiliations":[{"raw_affiliation_string":"Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;","institution_ids":["https://openalex.org/I1285204247"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Nicole Manning","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285204247","display_name":"Cincinnati Children's Hospital Medical Center","ror":"https://ror.org/01hcyya48","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285204247"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicole Manning","raw_affiliation_strings":["Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;","institution_ids":["https://openalex.org/I1285204247"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004664566","display_name":"Christina Sexton","orcid":"https://orcid.org/0009-0008-8423-4619","observed_orcids":["https://orcid.org/0009-0008-8423-4619"]},"institutions":[{"id":"https://openalex.org/I1285204247","display_name":"Cincinnati Children's Hospital Medical Center","ror":"https://ror.org/01hcyya48","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285204247"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christina Sexton","raw_affiliation_strings":["Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;","institution_ids":["https://openalex.org/I1285204247"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112551358","display_name":"Perentesis P John","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285204247","display_name":"Cincinnati Children's Hospital Medical Center","ror":"https://ror.org/01hcyya48","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285204247"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Perentesis P John","raw_affiliation_strings":["Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;","institution_ids":["https://openalex.org/I1285204247"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035455886","display_name":"Benjamin E. Mizukawa","orcid":"https://orcid.org/0000-0002-3312-2982","observed_orcids":["https://orcid.org/0000-0002-3312-2982"]},"institutions":[{"id":"https://openalex.org/I1285204247","display_name":"Cincinnati Children's Hospital Medical Center","ror":"https://ror.org/01hcyya48","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285204247"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin Mizukawa","raw_affiliation_strings":["Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"],"raw_orcid":"https://orcid.org/0000-0002-3312-2982","affiliations":[{"raw_affiliation_string":"Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;","institution_ids":["https://openalex.org/I1285204247"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000842818","display_name":"James C. Mulloy","orcid":"https://orcid.org/0009-0006-6265-938X","observed_orcids":["https://orcid.org/0009-0006-6265-938X"]},"institutions":[{"id":"https://openalex.org/I1285204247","display_name":"Cincinnati Children's Hospital Medical Center","ror":"https://ror.org/01hcyya48","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285204247"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James C. Mulloy","raw_affiliation_strings":["Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;","institution_ids":["https://openalex.org/I1285204247"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1285204247"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.2064,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.52176664,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"130","issue":null,"first_page":"1318","last_page":"1318"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.8378999829292297,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.8378999829292297,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.09470000118017197,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.026499999687075615,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/b-cell-acute-lymphoblastic-leukemia","display_name":"B-cell acute lymphoblastic leukemia","score":0.7760000228881836},{"id":"https://openalex.org/keywords/blinatumomab","display_name":"blinatumomab","score":0.9449999928474426},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8930000066757202},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/bispecific-t-cell-engagers","display_name":"bispecific T-cell engagers","score":0.8140000104904175},{"id":"https://openalex.org/keywords/humanized-mouse-model","display_name":"humanized mice","score":0.6759999990463257},{"id":"https://openalex.org/keywords/nsg-mice","display_name":"NSG mice","score":0.7160000205039978},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.6650000214576721},{"id":"https://openalex.org/keywords/t-cell-reconstitution","display_name":"T cell reconstitution","score":0.5270000100135803},{"id":"https://openalex.org/keywords/leukemia-relapse-prevention","display_name":"leukemia relapse prevention","score":0.3970000147819519}],"concepts":[{"id":"https://openalex.org/C2776156784","wikidata":"https://www.wikidata.org/wiki/Q3491954","display_name":"Humanized mouse","level":3,"score":0.7014648914337158},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5582472681999207},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5549646615982056},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.49555504322052},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.4925559163093567},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.454522043466568},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4532044231891632},{"id":"https://openalex.org/C2778086970","wikidata":"https://www.wikidata.org/wiki/Q514525","display_name":"Hematopoietic stem cell","level":4,"score":0.42527467012405396},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3923181891441345},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.37768232822418213},{"id":"https://openalex.org/C109159458","wikidata":"https://www.wikidata.org/wiki/Q919283","display_name":"Haematopoiesis","level":3,"score":0.3597291111946106},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.35024991631507874},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3044516290","doi":"https://doi.org/10.1182/blood.v130.suppl_1.1318.1318","is_oa":false,"landing_page_url":"https://ashpublications.org/blood/article/130/Supplement%201/1318/116293/PD-1-Inhibition-Enhances-Blinatumomab-Response-in","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Blood","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3157004930","https://openalex.org/W2885295219","https://openalex.org/W2768987490","https://openalex.org/W3216325059","https://openalex.org/W2809816873","https://openalex.org/W3081813211","https://openalex.org/W4313383726","https://openalex.org/W2887436211","https://openalex.org/W2904841252","https://openalex.org/W2461599536"],"abstract_inverted_index":{"Abstract":[0],"IL-2Ry":[3],"immune":[4,16,74,139,330,482,494],"deficient":[5],"mice":[6,35,52,97,122,129,148,179,210,257,283,290,347,382,430],"engrafted":[7,350],"with":[8,18,153,182,222,235,351,431,493],"human":[9,15,41,85,142,169,329],"umbilical":[10],"cord":[11],"blood":[12,155,176],"(UCB)":[13],"develop":[14],"systems":[17],"mixed":[19],"B,":[20],"T,":[21],"NK,":[22],"and":[23,32,45,56,64,72,84,95,216,231,252,275,365,387,486],"myeloid":[24,55],"populations.":[25],"We":[26,110],"have":[27,53],"previously":[28],"modified":[29],"NOD/SCID/Gamma":[30],"(NSG)":[31],"NOD/RAG/Gamma":[33],"(NRG)":[34],"to":[36,49,92,123,137,197,212,413,425,442,444,457,509],"include":[37],"transgenic":[38],"expression":[39],"of":[40,108,113,117,165,168,238,255,264,273,295,305,327,343,420,473,481,507],"cytokines":[42],"SCF,":[43],"GM-CSF,":[44],"IL-3":[46],"(NSGS/NRGS).":[47],"Relative":[48],"NSG/NRG,":[50],"NSGS/NRGS":[51],"increased":[54],"NK":[57],"fractions,":[58],"more":[59,99],"complete":[60],"B":[61],"cell":[62,67,156,185,242,358,376,392,416,461],"differentiation,":[63],"faster":[65],"T":[66,171,184,241,357,375,391,415,436,460],"reconstitution.":[68],"Additionally,":[69],"both":[70,385],"innate":[71],"adaptive":[73],"function":[75],"is":[76,404,453],"also":[77,98],"improved":[78,115],"as":[79,132],"measured":[80],"by":[81,151,162],"DTH":[82],"assay":[83],"antigen":[86],"specific":[87],"antibody":[88],"production":[89],"in":[90,105,120,134,173,187,201,226,307,345,381,394,438,484],"response":[91,462],"immunization.":[93],"NSGS":[94],"NRGS":[96,121,147,204,209],"readily":[100],"engraft":[101],"leukemia":[102,220],"samples,":[103],"particularly":[104],"the":[106,114,163,174,202,227,239,262,265,271,276,282,293,296,325,328,352,363,439,459,470],"absence":[107],"conditioning.":[109],"took":[111],"advantage":[112],"nature":[116],"hematopoietic":[118],"xenografts":[119],"determine":[124],"whether":[125],"or":[126,311,339,447],"not":[127,334],"humanized":[128,150,203,208],"can":[130],"serve":[131],"an":[133,191],"vivo":[135,485],"model":[136],"test":[138],"therapies":[140,483],"against":[141],"leukemia.":[143],"Busulfan":[145],"conditioned":[146],"were":[149,180,247,349,360,378],"engraftment":[152],"red":[154],"depleted":[157],"UCB.":[158],"Engraftment":[159],"was":[160,302,322],"monitored":[161,361],"appearance":[164],"significant":[166],"levels":[167,359,377],"CD45+CD3+":[170,435],"cells":[172,437],"peripheral":[175],"(PB).":[177],"Once":[178],"reconstituted":[181],">25%":[183],"graft":[186],"PB,":[188,228,308],"we":[189],"injected":[190],"aggressive,":[192],"relapsed/refractory":[193],"t(4;11)":[194],"patient":[195,354],"sample":[196],"induce":[198],"fatal":[199],"ALL":[200],"mice.":[205],"All":[206,287],"control":[207],"succumbed":[211],"disease":[213,306],"between":[214],"40":[215],"60":[217],"days":[218],"after":[219],"injection":[221],"rapidly":[223],"expanding":[224],"B-ALL":[225,260,285,344],"bone":[229,309],"marrow,":[230,310],"spleen.":[232],"Mice":[233],"treated":[234,289],"several":[236],"courses":[237],"bi-specific":[240],"engager":[243],"(BiTE)":[244],"molecule,":[245],"blinatumomab,":[246],"partially":[248],"protected":[249,281],"from":[250,284],"disease,":[251],"only":[253],"half":[254],"these":[256],"developed":[258],"detectable":[259],"at":[261,298],"end":[263,294],"experiment":[266,297,364],"(day":[267],"90":[268],"post-injection).":[269],"Strikingly,":[270],"combination":[272],"blinatumomab":[274,320,371,386,410,446],"PD-1":[277],"antibody,":[278],"pembrolizumab,":[279,388],"fully":[280],"disease.":[286],"blinatumomab/pembrolizumab":[288,449],"survived":[291],"until":[292],"which":[299],"time":[300],"there":[301,452],"no":[303],"evidence":[304],"spleen":[312],"preparations.":[313],"Importantly,":[314],"additional":[315,489],"experiments":[316],"showed":[317,366],"that":[318,348,383,406,488],"this":[319,427],"effect":[321],"dependent":[323],"on":[324],"presence":[326],"system.":[331],"Blinatumomab":[332],"did":[333],"affect":[335],"initiation":[336],"(early":[337],"treatment)":[338,342],"progression":[340],"(late":[341],"non-humanized":[346],"same":[353],"sample.":[355],"during":[362,463],"a":[367,399,454],"slight":[368],"decline":[369],"upon":[370],"treatment.":[372],"In":[373],"contrast,":[374],"significantly":[379],"higher":[380],"received":[384],"implying":[389],"augmented":[390],"activation":[393],"vivo.":[395],"This":[396],"may":[397,422],"be":[398],"relevant":[400,505],"finding":[401],"because":[402],"it":[403],"likely":[405],"some":[407],"patients":[408],"fail":[409],"therapy":[411],"due":[412],"sub-optimal":[414],"levels.":[417],"The":[418],"addition":[419],"pembrolizumab":[421],"offer":[423],"means":[424],"combat":[426],"problem.":[428],"Nevertheless,":[429],"less":[432],"than":[433],"20%":[434],"PB":[440],"failed":[441],"respond":[443],"either":[445],"combined":[448],"treatment,":[450],"indicating":[451],"lower":[455],"limit":[456],"potentiating":[458],"BiTE":[464],"therapy.":[465],"These":[467],"results":[468],"demonstrate":[469],"potential":[471],"utility":[472],"dual":[474],"UCB/PDX":[475],"models":[476],"for":[477],"examining":[478],"novel":[479],"combinations":[480],"suggest":[487],"studies":[490],"combining":[491],"BiTEs":[492],"checkpoint":[495],"inhibitors":[496],"are":[497],"warranted.":[498],"Disclosures":[502],"No":[504],"conflicts":[506],"interest":[508],"declare.":[510]},"counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2020-07-29T00:00:00"}